Targeting cancer-specific mutations by T cell receptor gene therapy
T Blankenstein, M Leisegang, W Uckert… - Current opinion in …, 2015 - Elsevier
Highlights•T cell therapy can eradicate large tumors.•Cancer-specific mutations creating
neoepitopes are potentially the best target.•Mutant epitopes can be retained in patients …
neoepitopes are potentially the best target.•Mutant epitopes can be retained in patients …
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Checkpoint blockade immunotherapies enable the host immune system to recognize and
destroy tumour cells. Their clinical activity has been correlated with activated T-cell …
destroy tumour cells. Their clinical activity has been correlated with activated T-cell …
[HTML][HTML] Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis
A Schietinger, M Philip, VE Krisnawan, EY Chiu… - Immunity, 2016 - cell.com
CD8+ T cells recognizing tumor-specific antigens are detected in cancer patients but are
dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a …
dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a …
Clonal evolution of glioblastoma under therapy
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better
understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data …
understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data …
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Somatic missense mutations can initiate tumorogenesis and, conversely, anti-tumor
cytotoxic T cell (CTL) responses. Tumor genome analysis has revealed extreme …
cytotoxic T cell (CTL) responses. Tumor genome analysis has revealed extreme …
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo… - Clinical Cancer …, 2015 - AACR
Purpose: Recent studies have shown that 7% to 12% of endometrial cancers are
ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA …
ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA …
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
WW Overwijk, E Wang, FM Marincola… - … for immunotherapy of …, 2013 - Springer
T cells can mediate remarkable tumor regressions including complete cure in patients with
metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode …
metastatic cancer. Genetic alterations in an individual's cancer cells (the mutanome) encode …
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for …
FA Eggink, IC Van Gool, A Leary, PM Pollock… - …, 2017 - Taylor & Francis
High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic
options are needed. Aims of this study were to validate the enhanced immune response in …
options are needed. Aims of this study were to validate the enhanced immune response in …
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines
Cancer cell lines are a tremendous resource for cancer biology and therapy development.
These multipurpose tools are commonly used to examine the genetic origin of cancers, to …
These multipurpose tools are commonly used to examine the genetic origin of cancers, to …
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
Somatic mutations in cancer are a potential source of cancer specific neoantigens. Acute
myeloid leukemia (AML) has common recurrent mutations shared between patients in …
myeloid leukemia (AML) has common recurrent mutations shared between patients in …